Adjunctive aripiprazole treatment for risperidone-induced hyperprolactinemia: An 8-week randomized, open-label, comparative clinical trial

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Zhao, Jingyuan ^a   Song, Xueqin ^b   Ai, Xiaoqing ^a   Gu, Xiaojing ^a   Huang, Guangbiao ^a   Li, Xue ^b   Pang, Lijuan ^b   Ding, Minli ^a   Ding, Shuang ^a   Lv, Luxian ^a  

^a XINXIANG MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROLACTIN; RISPERIDONE; TRIACYLGLYCEROL; ANTINEOPLASTIC AGENT; CHOLESTEROL; ETOPOSIDE; GLUCOSE BLOOD LEVEL; HIGH DENSITY LIPOPROTEIN; MITOXANTRONE; NEUROLEPTIC AGENT; PREDNISONE; VINCRISTINE;

ADULT; AKATHISIA; ARTICLE; BARNES AKATHISIA SCALE; CHINESE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERPROLACTINEMIA; HYPERSALIVATION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPEN STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS; SCHIZOPHRENIA; SOMNOLENCE; TRIACYLGLYCEROL BLOOD LEVEL; XEROSTOMIA; ANALYSIS; BLOOD; BODY MASS; CHEMICALLY INDUCED; COMPLICATION; DRUG ADMINISTRATION; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; HYPERPROLACTINEMIA; LIPOPROTEINS, HDL; MALE; MITOXANTRONE; PREDNISONE; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME; TRIGLYCERIDES; VINCRISTINE;

EID: 84948703104     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0139717     Document Type: Article

References (25)

1. Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003; 28 Suppl 2:55-68. PMID: 12650681
2. Leonard MP, Nickel CJ, Morales A. Hyperprolactinemia and impotence: why, when and how to investigate. The Journal of urology 1989; 142:992-994. PMID: 2795758
3. Paulzen M, Grunder G. Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole. The international journal of neuropsychopharmacology/official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2007; 10:149-151.
4. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-Analysis of randomized, controlled trials. The American journal of psychiatry 2003; 160:1209-1222. PMID: 12832232
5. Shim J-C, Shin J-G, Kelly D, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. American Journal of Psychiatry 2007; 164:1404-1410. PMID: 17728426
6. Byerly MJ, Marcus RN, Tran Q-V, Eudicone JM, Whitehead R, Baker RA. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophrenia research 2009; 107:218-222. doi: 10.1016/j.schres.2008.09.019 PMID: 19038534
7. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-Affinity partial agonist at human dopamine D2 receptors. The Journal of pharmacology and experimental therapeutics 2002; 302:381-389. PMID: 12065741
8. JK M, KL. G. Aripiprazole. Cns Drugs 2002; 16:779-786. PMID: 12383035
9. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. European Journal of Pharmacology 2002; 441:137-140. PMID: 12063084
10. Assembly WMAG. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects (revised October 7, 2000). Hiv Clinical Trials 2001; 27:235-237.
11. Segal DL. Diagnostic and statistical manual of mental disorders: DSM-IV-TR: Diagnostic and statistical manual of mental disorders: DSM-IV-TR; 2000.
12. Gssler N, Peuschel T, R. P. Pediatric reference values of estradiol, testosterone, lutropin, follitropin and prolactin. Clinical Laboratory 2000; 46:553-560. PMID: 11109502
13. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia bulletin 1987; 13:261-276. PMID: 3616518
14. Barnes TR. The Barnes Akathisia Rating Scale-Revisited. Journal of Psychopharmacology 2003; 17:365-370. PMID: 14870947
15. Lingjorde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross?sectional study of side effects in neuroleptic? treated patients. Acta Psychiatrica Scandinavica 1987; 76:1-100.
16. Lee B-H, Kim Y-K, Park S-H. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2006; 30:714-717. PMID: 16571367
17. Lu M-L, Shen WW, Chen C-H. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008; 32:1978-1981. doi: 10.1016/j.pnpbp.2008.09.016 PMID: 18848860
18. Yu R, Hsieh MH, Wang HLS, Liu CM, Liu CC, Hwang TJ, et al. Frequency Dependent Alterations in Regional Homogeneity of Baseline Brain Activity in Schizophrenia. Plos One 2013; 8:: e57516. doi: 10. 1371/journal.pone.0057516 PMID: 23483911
19. Kane JM, Correll CU, Goff DC, et al. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. The Journal of clinical psychiatry 2009; 70:1348-1357. doi: 10.4088/JCP.09m05154yel PMID: 19906340
20. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects. CNS drugs 2005; 19:1-93. PMID: 15998156
21. Tschoner A, Engl J, Laimer M, et al. Metabolic side effects of antipsychotic medication. International journal of clinical practice 2007; 61:1356-1370. PMID: 17627711
22. Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, et al. Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. Journal of Clinical Psychiatry 2008; 69:514. PMID: 18370570
23. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophrenia research 2004; 66:51-57. PMID: 14693352
24. Brixner DI, Said Q, Corey-Lisle PK, et al. Naturalistic impact of second-generation antipsychotics on weight gain. Annals of Pharmacotherapy 2006; 40:626-632. PMID: 16569802
25. Newcomer JW, Campos JA, Marcus RN, et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. Journal of Clinical Psychiatry 2008; 69:1046-1056. PMID: 18605811